Newfound Research LLC Vertex Pharmaceuticals Inc Transaction History

Newfound Research LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 15, 2022	SELL	$234.96 - $292.55 $114,895 - $143,056	-489 Closed	0 $0
Q1 2022 May 04, 2022	SELL	$221.42 - $260.97 $44,505 - $52,454	-201 Reduced 29.13%	489 $128,000
Q4 2021 Jan 19, 2022	BUY	$177.01 - $223.45 $20,002 - $25,249	113 Added 19.58%	690 $152,000
Q3 2021 Oct 14, 2021	BUY	$181.39 - $202.99 $34,101 - $38,162	188 Added 48.33%	577 $105,000
Q2 2021 Jul 19, 2021	BUY	$187.49 - $221.1 $6,937 - $8,180	37 Added 10.51%	389 $78,000
Q1 2021 Apr 28, 2021	BUY	$207.02 - $241.31 $35,607 - $41,505	172 Added 95.56%	352 $76,000
Q4 2020 Jan 22, 2021	BUY	$207.01 - $276.09 $15,525 - $20,706	75 Added 71.43%	180 $43,000
Q3 2020 Oct 20, 2020	BUY	$255.65 - $303.1 $26,843 - $31,825	105 New	105 $29,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Newfound Research LLC, based on Form 13F filings with the SEC.

Stay updated on Newfound Research LLC with notifications on news.